(RDNT) RadNet - Ratings and Ratios
MRI, CT, PET, Mammography, AI
RDNT EPS (Earnings per Share)
RDNT Revenue
Description: RDNT RadNet
RadNet Inc (NASDAQ:RDNT) is a healthcare services company providing outpatient diagnostic imaging services in the US and internationally, operating through two segments: Imaging Centers and Digital Health. The company offers a range of imaging services, including MRI, CT, PET, and mammography, as well as AI-powered health informatics solutions to enhance radiology operations.
From a business perspective, RadNets Imaging Centers segment is likely driven by key performance indicators (KPIs) such as scan volume, revenue per scan, and patient satisfaction. The Digital Health segment is likely evaluated on metrics such as software revenue, customer adoption rates, and the impact of AI solutions on radiologist accuracy and efficiency.
RadNets focus on AI-powered solutions, such as DeepHealth OS, suggests a strategic emphasis on leveraging technology to drive operational efficiency, improve patient outcomes, and potentially expand into new markets. The companys development of AI suites for breast, lung, and prostate imaging also indicates a focus on addressing specific clinical needs and potentially capitalizing on emerging trends in cancer screening and diagnosis.
To further analyze RadNets performance, additional KPIs to consider might include same-center sales growth, EBITDA margins, and return on invested capital (ROIC). The companys financial health could also be assessed by examining its debt-to-equity ratio, interest coverage, and cash flow generation. A review of industry trends, competitive landscape, and regulatory factors would also be necessary to contextualize RadNets position and prospects.
RDNT Stock Overview
| Market Cap in USD | 5,493m |
| Sub-Industry | Health Care Services |
| IPO / Inception | 1986-07-01 |
RDNT Stock Ratings
| Growth Rating | 47.1% |
| Fundamental | 56.0% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | -5.21% |
| Analyst Rating | 4.71 of 5 |
RDNT Dividends
Currently no dividends paidRDNT Growth Ratios
| Growth Correlation 3m | 72% |
| Growth Correlation 12m | -43.3% |
| Growth Correlation 5y | 79.3% |
| CAGR 5y | 55.20% |
| CAGR/Max DD 3y | 1.18 |
| CAGR/Mean DD 3y | 8.58 |
| Sharpe Ratio 12m | -0.22 |
| Alpha | 2.39 |
| Beta | 0.940 |
| Volatility | 36.77% |
| Current Volume | 678.5k |
| Average Volume 20d | 619k |
| Stop Loss | 71.5 (-3.4%) |
| Signal | 0.49 |
Piotroski VR‑10 (Strict, 0-10) 6.0
| Net Income (-14.9m TTM) > 0 and > 6% of Revenue (6% = 114.5m TTM) |
| FCFTA 0.03 (>2.0%) and ΔFCFTA 1.05pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 28.73% (prev 30.96%; Δ -2.22pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.07 (>3.0%) and CFO 261.8m > Net Income -14.9m (YES >=105%, WARN >=100%) |
| Net Debt (1.01b) to EBITDA (590.2m) ratio: 1.71 <= 3.0 (WARN <= 3.5) |
| Current Ratio 2.00 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (74.1m) change vs 12m ago 0.89% (target <= -2.0% for YES) |
| Gross Margin 30.28% (prev 10.00%; Δ 20.28pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 56.58% (prev 53.07%; Δ 3.51pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 1.26 (EBITDA TTM 590.2m / Interest Expense TTM 71.9m) >= 6 (WARN >= 3) |
Altman Z'' 1.07
| (A) 0.16 = (Total Current Assets 1.09b - Total Current Liabilities 546.2m) / Total Assets 3.51b |
| (B) -0.03 = Retained Earnings (Balance) -100.3m / Total Assets 3.51b |
| (C) 0.03 = EBIT TTM 90.9m / Avg Total Assets 3.37b |
| (D) -0.04 = Book Value of Equity -93.6m / Total Liabilities 2.34b |
| Total Rating: 1.07 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 56.03
| 1. Piotroski 6.0pt = 1.0 |
| 2. FCF Yield 1.90% = 0.95 |
| 3. FCF Margin 5.80% = 1.45 |
| 4. Debt/Equity 1.25 = 1.77 |
| 5. Debt/Ebitda 1.97 = 0.06 |
| 6. ROIC - WACC -4.00% = -5.00 |
| 7. RoE -1.64% = -0.27 |
| 8. Rev. Trend 98.00% = 4.90 |
| 9. Rev. CAGR 13.70% = 1.71 |
| 10. EPS Trend -21.42% = -0.54 |
| 11. EPS CAGR 0.0% = 0.0 |
What is the price of RDNT shares?
Over the past week, the price has changed by +2.81%, over one month by +7.65%, over three months by +28.87% and over the past year by +12.10%.
Is RadNet a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of RDNT is around 89.21 USD . This means that RDNT is currently undervalued and has a potential upside of +20.54% (Margin of Safety).
Is RDNT a buy, sell or hold?
- Strong Buy: 5
- Buy: 2
- Hold: 0
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the RDNT price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 77.4 | 4.6% |
| Analysts Target Price | 77.4 | 4.6% |
| ValueRay Target Price | 99.1 | 33.9% |
Last update: 2025-09-08 04:48
RDNT Fundamental Data Overview
CCE Cash And Equivalents = 833.2m USD (Cash And Short Term Investments, last quarter)
P/S = 2.8789
P/B = 5.8913
P/EG = 2.32
Beta = 1.545
Revenue TTM = 1.91b USD
EBIT TTM = 90.9m USD
EBITDA TTM = 590.2m USD
Long Term Debt = 1.08b USD (from longTermDebt, last quarter)
Short Term Debt = 85.0m USD (from shortTermDebt, last quarter)
Debt = 1.16b USD (Calculated: Short Term 85.0m + Long Term 1.08b)
Net Debt = 1.01b USD (from netDebt column, last quarter)
Enterprise Value = 5.82b USD (5.49b + Debt 1.16b - CCE 833.2m)
Interest Coverage Ratio = 1.26 (Ebit TTM 90.9m / Interest Expense TTM 71.9m)
FCF Yield = 1.90% (FCF TTM 110.7m / Enterprise Value 5.82b)
FCF Margin = 5.80% (FCF TTM 110.7m / Revenue TTM 1.91b)
Net Margin = -0.78% (Net Income TTM -14.9m / Revenue TTM 1.91b)
Gross Margin = 30.28% ((Revenue TTM 1.91b - Cost of Revenue TTM 1.33b) / Revenue TTM)
Tobins Q-Ratio = -62.18 (set to none) (Enterprise Value 5.82b / Book Value Of Equity -93.6m)
Interest Expense / Debt = 1.48% (Interest Expense 17.2m / Debt 1.16b)
Taxrate = 13.43% (6.03m / 44.9m)
NOPAT = 78.7m (EBIT 90.9m * (1 - 13.43%))
Current Ratio = 2.00 (Total Current Assets 1.09b / Total Current Liabilities 546.2m)
Debt / Equity = 1.25 (Debt 1.16b / last Quarter total Stockholder Equity 932.3m)
Debt / EBITDA = 1.97 (Net Debt 1.01b / EBITDA 590.2m)
Debt / FCF = 10.50 (Debt 1.16b / FCF TTM 110.7m)
Total Stockholder Equity = 907.0m (last 4 quarters mean)
RoA = -0.42% (Net Income -14.9m, Total Assets 3.51b )
RoE = -1.64% (Net Income TTM -14.9m / Total Stockholder Equity 907.0m)
RoCE = 4.58% (Ebit 90.9m / (Equity 907.0m + L.T.Debt 1.08b))
RoIC = 4.05% (NOPAT 78.7m / Invested Capital 1.94b)
WACC = 8.05% (E(5.49b)/V(6.65b) * Re(9.48%)) + (D(1.16b)/V(6.65b) * Rd(1.48%) * (1-Tc(0.13)))
Shares Correlation 3-Years: 78.79 | Cagr: 2.30%
Discount Rate = 9.48% (= CAPM, Blume Beta Adj.)
[DCF Debug] Terminal Value 76.92% ; FCFE base≈93.6m ; Y1≈115.5m ; Y5≈197.1m
Fair Price DCF = 33.66 (DCF Value 2.59b / Shares Outstanding 76.9m; 5y FCF grow 25.0% → 3.0% )
Revenue Correlation: 98.00 | Revenue CAGR: 13.70%
Rev Growth-of-Growth: -1.58
EPS Correlation: -21.42 | EPS CAGR: 0.0%
EPS Growth-of-Growth: 58.30
Additional Sources for RDNT Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle